This fall, The FDA recommended that Teva Neuroscience’s drug rasagiline, brand name Azilect, should not be granted status “to slow the clinical progression of PD.” In this podcast, Dave Iverson speaks with MJFF’s Brian Fiske about what this recommendation could mean for those living with PD.
To read more about the FDA's recommendation, check out this Fox Foundation News in Context with Parkinson's Progression Markers Initiative (PPMI) Principal Investigator Dr. Ken Marek.